Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Konopleva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Tech University Health Sciences Center at LubbockResidency, Internal Medicine, 2005 - 2008
St Petersburg Medical State AcademyClass of 1990
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2022 - 2026
TX State Medical License 2009 - 2024
OK State Medical License 2020 - 2021
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia Start of enrollment: 2009 Nov 01
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias Start of enrollment: 2010 Jun 01
- AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Oct 01
Publications & Presentations
PubMed
- 1 citationsAnalysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine.Marina Konopleva, Courtney D DiNardo, Yan Sun, Paul Jung, Sanam Loghavi
American Journal of Hematology. 2026-03-01 - First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.Naveen Pemmaraju, Marco Herling, Kendra L Sweet, Anthony S Stein, Sumithira Vasu
Haematologica. 2026-01-15 - Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.Nicholas J Short, Hagop Kantarjian, Nitin Jain, Tapan M Kadia, Jayastu Senapati
Blood Advances. 2026-01-13
Journal Articles
- CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic LeukemiaL Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular SubtypesKoichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
Abstracts/Posters
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaMarina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyMarina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Metabolism and Hematologic Malignancies60th American Society of Hematology Annual Meeting - 12/2/2018
- Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
Press Mentions
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) USA - English USA - EnglishMarch 20th, 2025
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)March 20th, 2025
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 8th, 2023
Grant Support
- Inhibition of Bcl-xL by Targeted DegradationUNIVERSITY OF FLORIDA2020–2025
- Targeting mitochondrial complex I in acute lymphoblastic leukemiaALBERT EINSTEIN COLLEGE OF MEDICINE2019–2025
- Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimenALBERT EINSTEIN COLLEGE OF MEDICINE2019–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










